ERNA — Ernexa Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Ernexa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -122 | -24.6 | -21.7 | -44.5 | -14.1 |
| Depreciation | |||||
| Non-Cash Items | 101 | -0.268 | 3.29 | 30.5 | 7.05 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.35 | 3.71 | -2.12 | -1.98 | -0.051 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -23.5 | -21 | -20.4 | -15.8 | -7.02 |
| Capital Expenditures | -0.154 | -0.297 | -0.019 | -0.369 | -0.037 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -22.6 | 0.25 | 0 | 0.004 | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -22.7 | -0.047 | -0.019 | -0.365 | -0.037 |
| Financing Cash Flow Items | — | -0.116 | -0.251 | 3.72 | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 61.6 | 19.6 | 16.6 | 6.26 | 7.21 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 15.4 | -1.44 | -3.87 | -9.94 | 0.155 |